Sino Biopharmaceutical Li... (SBMFF)
OTC: SBMFF
· Real-Time Price · USD
0.95
-0.04 (-3.94%)
At close: Aug 13, 2025, 12:40 PM
Sino Biopharmaceutical Cash Flow Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 3.5B | 3.26B | 3.65B | 2.77B | 1.57B | 1.88B | 2.21B | 2.54B | 5.3B | 8.05B | 13.66B | 14.61B | 12.46B | 10.04B | 3.84B |
Depreciation & Amortization | 510.23M | 510.23M | 836.84M | 908.32M | 932.64M | 1.21B | 1.09B | 967.54M | 942.9M | 918.25M | 713.92M | 509.58M | 254.79M | n/a | n/a |
Stock-Based Compensation | 53.72M | 26.86M | n/a | n/a | n/a | n/a | 14.86M | 29.72M | 29.72M | 29.72M | 14.86M | n/a | n/a | n/a | n/a |
Other Working Capital | n/a | n/a | n/a | n/a | 299.17M | 598.34M | 598.34M | 598.34M | 908.24M | 1.22B | 1.22B | 1.22B | 609.07M | n/a | n/a |
Other Non-Cash Items | -985.3M | -717.1M | -69.34M | 534.67M | 1.22B | 1.79B | 2.21B | 2.62B | 427.23M | -1.87B | -9.23B | -11.94B | -11.13B | -10.04B | -3.84B |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | n/a | n/a | n/a | 103.62M | -3.59M | -3.59M | -3.59M | -180.98M | -147.54M | -147.54M | -147.54M | -73.77M | n/a | n/a |
Operating Cash Flow | 3.08B | 3.08B | 4.41B | 4.21B | 3.83B | 4.99B | 5.63B | 6.27B | 6.62B | 6.98B | 5.01B | 3.03B | 1.52B | n/a | n/a |
Capital Expenditures | -407.5M | -407.5M | -784.45M | -957.66M | -1.06B | -1.37B | -1.31B | -1.24B | -1.5B | -1.76B | -1.44B | -1.13B | -564.26M | n/a | n/a |
Cash Acquisitions | n/a | n/a | 229K | 458K | 458K | 458K | 229K | n/a | -20.8M | -41.59M | -41.59M | -41.59M | -20.8M | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -1.63B | -1.63B | -3.29B | -4.14B | -2.05B | -786.06M | -1.81B | -2.83B | -2.74B | -2.65B | 28.76M | 2.71B | 1.36B | n/a | n/a |
Investing Cash Flow | -2.04B | -2.04B | -4.08B | -5.1B | -3.12B | -2.16B | -3.11B | -4.07B | -4.26B | -4.45B | -1.45B | 1.54B | 770M | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | -361.55M | -361.55M | -479.4M | -416.48M | -264.85M | -294M | -580.8M | -867.61M | -1B | -1.14B | -737.59M | -332.93M | -166.47M | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | -633.81M | -633.81M | -633.81M | -633.81M | -469.24M | -938.49M | -938.49M | -938.49M | -469.24M | n/a | n/a |
Other Financial Acitivies | -3.74B | -3.74B | -5.64B | -5.68B | -4.01B | -4.84B | -3.26B | -1.68B | -2.08B | -1.84B | -1.52B | -1.19B | -596.08M | n/a | n/a |
Financial Cash Flow | -4.1B | -4.1B | -6.12B | -6.09B | -4.91B | -5.77B | -4.48B | -3.19B | -3.56B | -3.92B | -3.19B | -2.46B | -1.23B | n/a | n/a |
Net Cash Flow | -3.04B | -3.04B | -5.72B | -6.88B | -4.07B | -2.77B | -1.86B | -944.73M | -1.45B | -1.96B | -195.84M | 1.57B | 785.61M | n/a | n/a |
Free Cash Flow | 2.67B | 2.67B | 3.63B | 3.25B | 2.77B | 3.62B | 4.32B | 5.02B | 5.12B | 5.22B | 3.56B | 1.9B | 951.11M | n/a | n/a |